Endocyte, Inc. Common Stock
ECYT
ECYT was delisted on the 20th of December, 2018.
2 hedge funds and large institutions have $1.45M invested in Endocyte, Inc. Common Stock in 2018 Q4 according to their latest regulatory filings, with 2 funds opening new positions, 0 increasing their positions, 0 reducing their positions, and 139 closing their positions.
99% less funds holding
Funds holding: 139 → 2 (-137)
99% less first-time investments, than exits
New positions opened: 2 | Existing positions closed: 139
100% less capital invested
Capital invested by funds: $1.11B → $1.45M (-$1.1B)
100% less funds holding in top 10
Funds holding in top 10: 8 → 0 (-8)
Top Buyers
| 1 |
OTC
Opera Trading Capital
Paris,
France
|
+$1.31M |
Top Sellers
| 1 |
RCM
RA Capital Management
Boston,
Massachusetts
|
-$110M |
| 2 |
ACA
Avoro Capital Advisors
New York
|
-$94.2M |
| 3 |
BlackRock
New York
|
-$93.7M |
| 4 |
VMI
VHCP Management II
New York
|
-$74.8M |
| 5 |
Vanguard Group
Malvern,
Pennsylvania
|
-$62.6M |
ECYT Hedge Fund Activity: Q4 2018 in Review
2 of the 4,488 institutional investors tracked by Wall St. Rank reported a position in Endocyte, Inc. Common Stock (ECYT) for Q4 2018, worth a combined $1.45M — down 100% from $1.11B a quarter earlier.
Sellers outnumbered buyers: 139 funds closed out of ECYT and 2 opened new positions — a net loss of 137 holders — while 0 trimmed existing stakes and 0 added.
The largest buyer was Opera Trading Capital, opening a new position worth an estimated $1.31M. The largest seller was RA Capital Management, exiting entirely with an estimated $110M sold.
- 2 institutional investors held Endocyte, Inc. Common Stock (ECYT) as of Q4 2018, down from 139 in Q3 2018.
- Funds reported $1.45M of Endocyte, Inc. Common Stock stock for Q4 2018, down 100% quarter-over-quarter.
- 2 funds opened new Endocyte, Inc. Common Stock positions in Q4 2018 and 139 closed out, a net change of -137 holders.
- The largest Endocyte, Inc. Common Stock buyer in Q4 2018 was Opera Trading Capital, an estimated $1.31M added.
- The largest Endocyte, Inc. Common Stock seller in Q4 2018 was RA Capital Management, an estimated $110M sold.
Based on aggregated 13F filings for Q4 2018.